Skip to main content
  • Saved

made a Post

Lower-Sodium Oxybate Dose Titration and Transition From Sodium Oxybate in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adult Participants With Narcolepsy With Cataplexy (2163)

Lower-Sodium Oxybate Dose Titration and Transition From Sodium Oxybate in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adult Participants With Narcolepsy With Cataplexy (2163)

Source :

https://n.neurology.org/content/96/15_Supplement/2163

Objective: Evaluate dose adjustment of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate, LXB; Xywav™; previously designated as JZP-258) during titration in a double-blind, placebo-controlled, randomized withdrawal study. Background: Sodium oxybate (SXB; Xyrem®) is a standard of care for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy.